Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.